ProCE Banner Activity

Regional Perspectives on Current Management of Advanced EGFR-Mutated Non-Small-Cell Lung Cancer

Clinical Thought
Thoracic oncologists Enriqueta Felip, MD, and Matthew Gubens, MD, MS, consider evolving practice standards for EGFR-mutated NSCLC in the EU and US.

Released: April 20, 2021

Expiration: April 19, 2022

No longer available for credit.

Share

Faculty

Enriqueta Felip

Enriqueta Felip, MD

Head, Thoracic Oncology Unit
Oncology Service
Vall d Hebron University Hospital
Barcelona, Spain

Matthew Gubens

Matthew Gubens, MD, MS

Associate Professor
Thoracic Oncology
University of California, San Francisco
San Francisco, California

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an educational grant from

AstraZeneca

Faculty Disclosure

Primary Author

Enriqueta Felip, MD

Head, Thoracic Oncology Unit
Oncology Service
Vall d Hebron University Hospital
Barcelona, Spain

Enriqueta Felip, MD, has disclosed that she has received consulting fees from AbbVie, Amgen, AstraZeneca, Bayer, Blueprint, Boehringer Ingelheim, Bristol-Myers Squibb, GlaxoSmithKline, Janssen, Lilly, Merck KGaA, Merck Sharp & Dohme, Novartis, Pfizer, Puma, Roche, Sanofi Genzyme, Takeda; fees for Non-CME/CE services from AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Lilly, Merck Sharp & Dohme, Novartis, Pfizer, Roche, and Takeda; funds for research support from Fundación Merck Salud; and other financial or material support from Grifols (independent member of the board).

Matthew Gubens, MD, MS

Associate Professor
Thoracic Oncology
University of California, San Francisco
San Francisco, California

Matthew Gubens, MD, MS, has disclosed that he has received funds for research support paid to his institution from Celgene, Merck, Novartis, OncoMed, and Roche and consulting fees from AstraZeneca, Beyond Spring, Boehringer Ingelheim, Bristol-Myers Squibb, Inivata, and Takeda.